MPLT.US MapLight Therapeutics, Inc. Common Stock

Healthcare Biotechnology USA Stocks
7.62 USD
Close of Nov 15, 2026
6.06 40.43
Market cap
USD 403M
P/E
-
P/B
1.16x
ROE
-69.4%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is MPLT.US undervalued?

Graham number

The Graham number of MapLight Therapeutics, Inc. Common Stock cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

MapLight Therapeutics, Inc. Common Stock fundamental analysis

No fundamental analysis for MapLight Therapeutics, Inc. Common Stock yet.

MapLight Therapeutics, Inc. Common Stock stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About MapLight Therapeutics, Inc. Common Stock

MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders. The company's products include ML-007C-MA, a fixed-dose combination of an M 1 /M 4 muscarinic agonist for the treatment of schizophrenia and Alzheimer's disease psychosis; ML-004 for the treatment of social communication deficit and/or irritability in autism spectrum disorder; ML-021 for the treatment of motor deficits …

Full company profile